Literature DB >> 24762290

Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease.

R Lorenz1, S Samnick, U Dillmann, M Schiller, M F Ong, K Faßbender, A Buck, J Spiegel.   

Abstract

BACKGROUND: Idiopathic Parkinson's disease (IPD) is characterized by the clinical motor symptoms of hypokinesia, rigidity, and tremor. Apart from these motor symptoms, cognitive deficits often occur in IPD. The positive effect of cholinesterase inhibitors on cognitive deficits in IPD and findings of earlier molecular imaging studies suggest that the cholinergic system plays an important role in the origin of cognitive decline in IPD.
METHODS: Twenty-five non-demented patients with IPD underwent a 5-[123I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380) SPECT to visualize α4β2 nicotinic acetylcholine receptors (nAchR) and cognitive testing with the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) battery to identify domains of cognitive dysfunction.
RESULTS: In the CERAD, the IPD patients exhibited deficits in non-verbal memory, attention, psychomotor velocity, visuoconstructive ability, and executive functions. After Bonferroni correction for multiple comparisons, we found significant correlations between performance of the CERAD subtests Boston Naming Test (a specific test for visual perception and for detection of word-finding difficulties) and Word List Intrusions (a specific test for learning capacity and memory for language information) vs binding of α4β2 nAchR in cortical (the right superior parietal lobule) and subcortical areas (the left thalamus, the left posterior subcortical region, and the right posterior subcortical region).
CONCLUSIONS: These significant correlations between the results of the CERAD subtests and the cerebral α4β2 nAchR density, as assessed by 5-I-A-85380 SPECT, indicate that cerebral cholinergic pathways are relevant to cognitive processing in IPD.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  5-I-A-85380-SPECT; Parkinson's disease; cognitive deficits; α4β2 nicotinic acetylcholine receptors

Mesh:

Substances:

Year:  2014        PMID: 24762290     DOI: 10.1111/ane.12259

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  8 in total

1.  Mechanisms of inhibition and potentiation of α4β2 nicotinic acetylcholine receptors by members of the Ly6 protein family.

Authors:  Meilin Wu; Clare A Puddifoot; Palmer Taylor; William J Joiner
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

Review 2.  The Cholinergic Brain in Parkinson's Disease.

Authors:  Jacopo Pasquini; David J Brooks; Nicola Pavese
Journal:  Mov Disord Clin Pract       Date:  2021-08-23

Review 3.  Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease.

Authors:  George E Barreto; Alexander Iarkov; Valentina Echeverria Moran
Journal:  Front Aging Neurosci       Date:  2015-01-09       Impact factor: 5.750

Review 4.  Can neuroimaging predict dementia in Parkinson's disease?

Authors:  Juliette H Lanskey; Peter McColgan; Anette E Schrag; Julio Acosta-Cabronero; Geraint Rees; Huw R Morris; Rimona S Weil
Journal:  Brain       Date:  2018-09-01       Impact factor: 13.501

5.  Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease.

Authors:  Ioannis Ugo Isaias; Jörg Spiegel; Joachim Brumberg; Kelly P Cosgrove; Giorgio Marotta; Naoya Oishi; Takahiro Higuchi; Sebastian Küsters; Markus Schiller; Ulrich Dillmann; Christopher H van Dyck; Andreas Buck; Ken Herrmann; Susanne Schloegl; Jens Volkmann; Michael Lassmann; Klaus Fassbender; Reinhard Lorenz; Samuel Samnick
Journal:  Front Aging Neurosci       Date:  2014-08-14       Impact factor: 5.750

Review 6.  Cholinergic imaging in dementia spectrum disorders.

Authors:  Roman Roy; Flavia Niccolini; Gennaro Pagano; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-16       Impact factor: 9.236

7.  Radiation dosimetry of [(18)F]VAT in nonhuman primates.

Authors:  Morvarid Karimi; Zhude Tu; Xuyi Yue; Xiang Zhang; Hongjun Jin; Joel S Perlmutter; Richard Laforest
Journal:  EJNMMI Res       Date:  2015-12-10       Impact factor: 3.138

Review 8.  Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease.

Authors:  Santiago Perez-Lloret; Francisco J Barrantes
Journal:  NPJ Parkinsons Dis       Date:  2016-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.